Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.62 |
| ▸ | CDK2 | P24941 | 12/20 | 0.62 |
| ▸ | SGK1 | O00141 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744170 | 1.00 | AKT1 (0.62) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL2546724 | 1.00 | AKT1 (0.62) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL12267334 | 0.93 | AKT1 (0.67) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL1742878 | 0.93 | AKT1 (0.67) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL2543364 | 0.89 | AKT1 (0.72) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL2543360 | 0.89 | AKT1 (0.72) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL1741865 | 0.89 | AKT1 (0.72) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL12241486 | 0.88 | AKT1 (0.62) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL12241768 | 0.88 | AKT1 (0.62) | AKT1CDK2SGK1CDK1KIT | |
| SCHEMBL12241847 | 0.88 | AKT1 (0.74) | AKT1CDK2SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | AKT1 74/4885CDK2 151/4885SGK1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.